Literature DB >> 8931947

Structure determination of metabolites isolated from urine and bile after administration of AY4166, a novel D-phenylalanine-derivative hypoglycemic agent.

H Takesada1, K Matsuda, R Ohtake, R Mihara, I Ono, K Tanaka, M Naito, M Yatagai, E Suzuki.   

Abstract

Molecular structures of 10 metabolites, which were isolated from urine (M1-M8) or bile (M9 and M10) after administration of AY4166 (N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine), a novel amino acid derivative with hypoglycemic activity, have been elucidated by mass spectrometry and nuclear magnetic resonance. Four of these (M1, M2, M3 and M8) were determined to be hydroxyl derivatives of AY4166, two (M9 and M10) were carboxylate derivatives via oxidization of M2 and M3, three (M4, M5 and M6) were glucronic acid conjugates and the other (M7) was a dehydro derivative. The estimated structures for M1, M2, M3, M7, M8, M9 and M10 were confirmed by the coincidence of the retention time of HPLC, MS and 1H NMR spectra between the isolated metabolites and authentic synthesized substances. For three glucronic acid conjugates, M4, M5 and M6, structural confirmation was performed by a selective enzymatic digestion with beta-glucronidase. M1 and M2/3 were about 5-6 and 3 times less potent than AY4166, respectively, and M7 was almost as potent as AY4166.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8931947     DOI: 10.1016/0968-0896(96)00187-3

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  7 in total

Review 1.  Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.

Authors:  Julia Kirchheiner; Ivar Roots; Mark Goldammer; Bernd Rosenkranz; Jürgen Brockmöller
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide.

Authors:  Mikko Niemi; Janne T Backman; Laura Juntti-Patinen; Mikko Neuvonen; Pertti J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  2005-08       Impact factor: 4.335

Review 3.  Nateglinide.

Authors:  C J Dunn; D Faulds
Journal:  Drugs       Date:  2000-09       Impact factor: 9.546

4.  Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers.

Authors:  Julia Kirchheiner; Ingolf Meineke; Göran Müller; Steffen Bauer; Wolfgang Rohde; Christian Meisel; Ivar Roots; Jürgen Brockmöller
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

5.  Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects.

Authors:  Mikko Niemi; Janne T Backman; Mikko Neuvonen; Pertti J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

Review 6.  Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent.

Authors:  James F McLeod
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 7.  A review of nateglinide in the management of patients with type 2 diabetes.

Authors:  Nicholas Tentolouris; Christina Voulgari; Nicholas Katsilambros
Journal:  Vasc Health Risk Manag       Date:  2007
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.